Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as 'compassionate use.'
NEW YORK, March 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the treatment of dermatological conditions associated with cancer therapy.
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as 'compassionate use.'
'Submitting an Expanded Access application is an important step in our commitment to ensuring patients who may benefit from HT-001 have the opportunity to receive this promising treatment,' said Robb Knie, CEO of Hoth Therapeutics. 'We remain dedicated to advancing solutions that address critical unmet medical needs and improve quality of life for patients undergoing cancer treatment.'
The Expanded Access Program is designed to provide investigational treatments to patients with serious or life-threatening conditions who lack comparable treatment options. Through this program, Hoth Therapeutics seeks to offer HT-001 to eligible patients while continuing to gather valuable data on its safety and efficacy.
For more information about HT-001, ongoing clinical trials, or the Expanded Access Program, please visit www.hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as 'could,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'may,' 'continue,' 'predict,' 'potential,' 'project' or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled 'Risk Factors' in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
an hour ago
- Business Insider
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) Receives a Buy from Bell Potter
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report), with a price target of A$2.25. The company's shares closed last Friday at A$1.17. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jacobs covers the Healthcare sector, focusing on stocks such as EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, Trajan Group Holdings Ltd, and Medical Developments International Limited. According to TipRanks, Jacobs has an average return of -21.1% and a 13.58% success rate on recommended stocks. Currently, the analyst consensus on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is a Strong Buy with an average price target of A$2.80, implying a 140.34% upside from current levels. In a report released on May 29, Wilsons also maintained a Buy rating on the stock with a A$3.00 price target.
Yahoo
2 hours ago
- Yahoo
SK hynix Presents Future DRAM Technology Roadmap at IEEE VLSI 2025
- SK hynix participates in IEEE VLSI symposium 2025 in Kyoto, Japan June 8-12 - Considering switching to 4F² VG platform from 10-nm level technology due to scaling limitation with current DRAM technology - Company to present long-term technological vision and work with industry to bring future of DRAM into reality SEOUL, South Korea, June 9, 2025 /PRNewswire/ -- SK hynix Inc. (or "the company", announced today that it presented a new DRAM technology roadmap for the next 30 years and the direction for a sustainable innovation at the IEEE VLSI symposium 2025* held in Kyoto, Japan. * IEEE VLSI (Institute of Electrical and Electronics Engineers Very Large Scale Integration) symposium: One of the most prestigious academic events in the field of semiconductor circuit and process technology, presenting academic achievement in next-generation semiconductor, AI, memory chip and packaging. The symposium is held in turn in United States and Japan annually. Cha Seon Yong, Chief Technology Officer (CTO) of SK hynix, delivered on June 10th a plenary session on "Driving Innovation in DRAM Technology: Towards a Sustainable Future". In his speech, CTO Cha explained that it is increasingly difficult to improve performance and capacity with scaling through current technology platform*. "In order to overcome such limitations, SK hynix will apply the 4F² VG (Vertical Gate) platform and 3D DRAM technology to technologies of 10-nanometer level or below with innovation in structure, material and components," he said. * Tech Platform: A technological framework that can be applied to various generations of products The 4F²* VG** platform is a next-generation memory technology that minimizes the cell area of DRAM and enables high-integration, high-speed and low-power through a vertical gate structure. * 4F²: The area occupied by one cell, a unit to store data, is indicated as F2. F indicates the minimum feature size of a semiconductor. Therefore, 4F2 is an integration technology to put more cells in a chip which one cell occupies an area of 2F by 2F. ** VG (Vertical Gate): A structure that a gate, which acts as a switch of a transistor, is vertically placed and surrounded by channels. Currently, it is a flat structure where a gate is laid horizontally on top of channels. Currently, 6F2 cells are common, but by applying 4F2 cell and wafer bonding technology that puts the circuit part below the cell area, cell efficiency and electrical characteristics can be improved. CTO Cha also introduced 3D DRAM as the main pillar for the future DRAM along with VG. CTO Cha said that although some in the industry warn of cost increase according to the number of layers stacked, it can be solved by constant technological innovation. Along with structural breakthrough, the company will also strive to find a new growth engine by sophisticating technologies of critical materials and components of DRAM to lay foundation for the next 30 years. "Until around 2010, DRAM technology was expected to face limitations at 20 nanometers, but with constant innovation, we have made it this far," said CTO Cha. "SK hynix will continue to guide the future of long-term technological innovation to be a milestone for young engineers in the field of DRAM and maintain cooperation within the industry to bring future of DRAM into reality." On the last day of the event, Joodong Park, vice president who leads the Next Gen DRAM TF, will present his findings from a recent research on how VG and wafer bonding technology affect the electrical characteristics of DRAM. About SK hynix Inc. SK hynix Inc., headquartered in Korea, is the world's top tier semiconductor supplier offering Dynamic Random Access Memory chips ("DRAM") and flash memory chips ("NAND flash") for a wide range of distinguished customers globally. The Company's shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at View original content: SOURCE SK hynix Inc.
Yahoo
2 hours ago
- Yahoo
Riot Platforms, Inc. (RIOT) Outperforms Broader Market: What You Need to Know
Riot Platforms, Inc. (RIOT) closed the latest trading day at $10.11, indicating a +2.64% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. The company's stock has climbed by 16.16% in the past month, exceeding the Finance sector's gain of 5.44% and the S&P 500's gain of 7.21%. Investors will be eagerly watching for the performance of Riot Platforms, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.26, up 18.75% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $142.25 million, up 103.15% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.53 per share and revenue of $623.25 million, which would represent changes of -550% and +65.47%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Riot Platforms, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.52% lower. As of now, Riot Platforms, Inc. holds a Zacks Rank of #5 (Strong Sell). The Financial - Miscellaneous Services industry is part of the Finance sector. With its current Zacks Industry Rank of 141, this industry ranks in the bottom 43% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Riot Platforms, Inc. (RIOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data